Immix Biopharma Expands Clinical Trial Sites for NEXICART-2
Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company, has made important strides with its NEXICART-2 clinical trial, which focuses on patients with relapsed/refractory AL Amyloidosis. This expansion is vital for enhancing patient access and boosting enrollment in a study that evaluates the safety and efficacy of CAR-T therapy, specifically CAR-T NXC-201.
New Clinical Trial Sites
The addition of new clinical trial sites will significantly increase opportunities for patient participation across the United States. Noteworthy locations such as Cleveland Clinic, UC Davis, and Sutter Health are now part of the trial. The lead institution, Memorial Sloan Kettering Cancer Center (MSKCC), continues to drive this initiative, providing a strong foundation for the study.
Positive Data from Previous Studies
Recent results from the ex-U.S. clinical trial, shared at the American Society of Gene and Cell Therapy (ASGCT) 2024, showcased an impressive 92% overall response rate among patients receiving treatment. This data underscores the potential of CAR-T NXC-201 in this therapeutic area, marking a significant achievement for Immix Biopharma's innovative approach to treating AL amyloidosis.
Overview of the NEXICART-2 Study
The NEXICART-2 study (NCT06097832) is structured as an open-label, single-arm trial aimed at assessing the effectiveness of CAR-T NXC-201 in patients with relapsed/refractory AL Amyloidosis. It targets individuals who have adequate cardiac function and have not previously received BCMA-targeted therapy, with plans to enroll up to 40 participants. This trial design includes a safety run-in phase to ensure patient safety across different doses of CAR-T cells.
Expected Outcomes of the Clinical Trial
In the NEXICART-2 trial, the primary endpoints are complete response rates and overall response rates, which are essential metrics for evaluating treatment efficacy. The study aims to validate earlier findings by further investigating the effects of escalating doses of CAR-T NXC-201 among the patient cohort.
Details on NXC-201
NXC-201 is Immix Biopharma's leading candidate, representing a significant advancement in CAR-T therapies specifically designed for AL amyloidosis. This therapy has been engineered for steric optimization, enhancing its effectiveness while minimizing potential side effects. Initial results from the Phase 1b/2 ex-U.S. study have indicated a promising safety profile, with no reported neurotoxicity among treated patients.
Market Significance of AL Amyloidosis
AL amyloidosis poses a substantial challenge in healthcare, characterized by the abnormal buildup of amyloid proteins that can lead to organ dysfunction and increased mortality rates. Recent estimates suggest that the prevalence of relapsed/refractory AL amyloidosis is rising, with approximately 33,277 individuals affected. The market for treatments targeting AL amyloidosis is valued at $3.6 billion and is projected to grow significantly, potentially reaching $6 billion in the coming years.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. is at the forefront of developing innovative cell therapies for AL amyloidosis and other immune-mediated diseases. The company is committed to advancing its clinical programs, particularly NXC-201, which has received Orphan Drug Designation from both the FDA and the EMA, highlighting its potential to meet significant medical needs.
Contact Information
For more information about Immix Biopharma and its clinical trials, please contact Mike Moyer at LifeSci Advisors via email at mmoyer@lifesciadvisors.com or reach out to the company's investor relations team at irteam@immixbio.com.
Frequently Asked Questions
What is the purpose of the NEXICART-2 trial?
The NEXICART-2 trial aims to evaluate the safety and efficacy of the CAR-T NXC-201 therapy in patients with relapsed/refractory AL amyloidosis.
How many patients will be enrolled in the NEXICART-2 study?
Up to 40 patients with adequate cardiac function who have not been previously treated with BCMA-targeted therapy will be enrolled.
What results were reported from the ASGCT 2024 regarding CAR-T NXC-201?
The ASGCT 2024 presented data indicating a remarkable 92% overall response rate for patients treated with CAR-T NXC-201.
What are the primary endpoints of the trial?
The primary endpoints include the complete response rate and overall response rate, which are critical for determining the treatment's success.
What is the significance of Orphan Drug Designation for NXC-201?
Orphan Drug Designation enhances the development of NXC-201, providing benefits such as market exclusivity and incentives to promote research on conditions with limited treatment options.
